We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+33.99%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.2B
AUM Growth
+$88.2M
Cap. Flow
-$49.3M
Cap. Flow %
-4.12%
Top 10 Hldgs %
81.29%
Holding
35
New
8
Increased
4
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$51.9M
2
SAGE
Sage Therapeutics
SAGE
+$44.1M
3
SCPH
scPharmaceuticals
SCPH
+$40.3M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$18.7M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$16M

Top Sells

Rank Stock Value
1
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$54.3M
2
RXDX
Ignyta, Inc.
RXDX
+$50.7M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$47.4M
4
INSM icon
Insmed
INSM
+$22.6M
5
ACOR
Acorda Therapeutics
ACOR
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$264M 22.06%
7,512,049
+423,398
+6% +$12.3M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.5B
$224M 18.71%
5,580,690
– –
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$130M 10.85%
1,171,278
-66,903
-5% -$6.72M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$75M 6.27%
+455,173
New +$44.1M
IFRX icon
5
InflaRx
IFRX
$243M
$60.3M 5.04%
+2,876,080
New +$51.9M
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$53.9M 4.51%
1,997,278
– –
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$45.9M 3.84%
1,145,268
+153,000
+15% +$5.88M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$44.8M 3.75%
4,965,513
+2,536,942
+104% +$18.7M
KALA icon
9
KALA BIO
KALA
$12.5M
$39.1M 3.27%
846
– –
MYOV
10
DELISTED
Myovant Sciences Ltd.
MYOV
$35.8M 2.99%
2,830,455
– –
SCPH
11
DELISTED
scPharmaceuticals
SCPH
$34.5M 2.89%
+2,857,143
New +$40.3M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.42B
$34.3M 2.87%
6,984,692
– –
KDMN
13
DELISTED
Kadmon Holdings, Inc.
KDMN
$22.7M 1.9%
6,269,342
-397,324
-6% -$1.42M
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$19.5M 1.63%
+900,000
New +$13.2M
SPRO icon
15
Spero Therapeutics
SPRO
$68.9M
$14.4M 1.21%
+1,225,647
New +$15M
ECYT
16
DELISTED
Endocyte, Inc. Common Stock
ECYT
$14.4M 1.21%
+3,364,648
New +$16M
AVEO
17
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$14.1M 1.18%
506,276
-626,589
-55% -$19.5M
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$14.1M 1.18%
1,441,070
+850,000
+144% +$8.85M
RARX
19
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$11.5M 0.96%
1,351,808
– –
VIRX
20
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$11.4M 0.96%
+88,481
New +$8.29M
CMTA
21
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$11.1M 0.93%
585,403
– –
KRYS icon
22
Krystal Biotech
KRYS
$10.7B
$7.36M 0.62%
700,000
– –
ARGX icon
23
argenx
ARGX
$55.2B
$4.79M 0.4%
+75,816
New +$2.48M
GTHX
24
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.17M 0.27%
159,780
-2,524,464
-94% -$54.3M
TARA icon
25
Protara Therapeutics
TARA
$214M
$2.54M 0.21%
33,437
– –
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, RA Capital Management held 35 positions worth $1.2B, up 8% from $1.11B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

RA Capital Management withdrew a net $49.3M in Q4 2017, closing 8 positions and reducing 6 holdings. Its most notable exit was Ignyta, Inc., an estimated $50.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier.

Against the trend, RA Capital Management opened a new position in InflaRx worth $60.3M.

  • RA Capital Management's largest Q4 2017 buy was InflaRx: 2,876,080 shares worth $60.3M.
  • RA Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q4 2017, an estimated $18.7M increase.
  • RA Capital Management's biggest Q4 2017 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $54.3M.
  • RA Capital Management fully exited Ignyta, Inc. in Q4 2017, selling an estimated $50.7M.
  • RA Capital Management's ten largest holdings make up 81% of its $1.2B portfolio in Q4 2017.
  • RA Capital Management opened 8 new positions and closed 8 in Q4 2017.
  • RA Capital Management's portfolio value rose 8% quarter-over-quarter to $1.2B.

Based on RA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.